We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In the latest close session, Eli Lilly (LLY - Free Report) was up +1.51% at $738.17. The stock outpaced the S&P 500's daily gain of 0.21%. Elsewhere, the Dow gained 0.25%, while the tech-heavy Nasdaq added 0.45%.
Shares of the drugmaker have appreciated by 16.23% over the course of the past month, outperforming the Medical sector's gain of 5.47%, and the S&P 500's gain of 3.07%.
Analysts and investors alike will be keeping a close eye on the performance of Eli Lilly in its upcoming earnings disclosure. In that report, analysts expect Eli Lilly to post earnings of $6.42 per share. This would mark year-over-year growth of 444.07%. In the meantime, our current consensus estimate forecasts the revenue to be $16.05 billion, indicating a 40.32% growth compared to the corresponding quarter of the prior year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $23.03 per share and revenue of $61.81 billion, which would represent changes of +77.29% and +37.22%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for Eli Lilly. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 5.18% higher. Eli Lilly presently features a Zacks Rank of #3 (Hold).
With respect to valuation, Eli Lilly is currently being traded at a Forward P/E ratio of 31.58. This expresses a premium compared to the average Forward P/E of 14.41 of its industry.
One should further note that LLY currently holds a PEG ratio of 1.02. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. LLY's industry had an average PEG ratio of 1.37 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 160, finds itself in the bottom 36% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Eli Lilly (LLY) Laps the Stock Market: Here's Why
In the latest close session, Eli Lilly (LLY - Free Report) was up +1.51% at $738.17. The stock outpaced the S&P 500's daily gain of 0.21%. Elsewhere, the Dow gained 0.25%, while the tech-heavy Nasdaq added 0.45%.
Shares of the drugmaker have appreciated by 16.23% over the course of the past month, outperforming the Medical sector's gain of 5.47%, and the S&P 500's gain of 3.07%.
Analysts and investors alike will be keeping a close eye on the performance of Eli Lilly in its upcoming earnings disclosure. In that report, analysts expect Eli Lilly to post earnings of $6.42 per share. This would mark year-over-year growth of 444.07%. In the meantime, our current consensus estimate forecasts the revenue to be $16.05 billion, indicating a 40.32% growth compared to the corresponding quarter of the prior year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $23.03 per share and revenue of $61.81 billion, which would represent changes of +77.29% and +37.22%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for Eli Lilly. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 5.18% higher. Eli Lilly presently features a Zacks Rank of #3 (Hold).
With respect to valuation, Eli Lilly is currently being traded at a Forward P/E ratio of 31.58. This expresses a premium compared to the average Forward P/E of 14.41 of its industry.
One should further note that LLY currently holds a PEG ratio of 1.02. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. LLY's industry had an average PEG ratio of 1.37 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 160, finds itself in the bottom 36% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.